Overview

• Biopharmaceutical firm's Q4 revenue missed analyst expectations

• Net loss for Q4 widened compared to the previous year

• Company ended 2025 with $1.6 bln cash, runway into 2029

Outlook

• Kymera expects data from KT-621 Phase 2b trials in mid-2027 and late-2027

• Company anticipates KT-579 Phase 1 trial data in second half of 2026

• Kymera projects cash runway into 2029 with $1.6 bln in cash

Result Driver

• R&D EXPENSES - Increased due to investment in STAT6 program and discovery initiatives

Company press release: ID:nGNXc5PvnQ

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Miss	$2.87 mln	$15.05 mln (20 Analysts)
Q4 EPS		-$0.97
Q4 Net Income		-$86.98 mln
Q4 Operating Expenses		$100.77 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Kymera Therapeutics Inc is $116.00, about 27.9% above its February 25 closing price of $90.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.